Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Revenue (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Revenue over the past 12 years, most recently at $132000.0 for Q4 2025.

  • Quarterly results put Revenue at $132000.0 for Q4 2025, up 83.33% from a year ago — trailing twelve months through Dec 2025 was $70.8 million (up 23359.93% YoY), and the annual figure for FY2025 was $70.8 million, up 23359.93%.
  • Revenue for Q4 2025 was $132000.0 at Viridian Therapeutics, Inc.\DE, down from $70.6 million in the prior quarter.
  • Over the last five years, Revenue for VRDN hit a ceiling of $70.6 million in Q3 2025 and a floor of $72000.0 in Q2 2023.
  • Median Revenue over the past 5 years was $101500.0 (2022), compared with a mean of $3.8 million.
  • Biggest five-year swings in Revenue: crashed 93.97% in 2023 and later surged 81958.14% in 2025.
  • Viridian Therapeutics, Inc.\DE's Revenue stood at $214000.0 in 2021, then crashed by 50.93% to $105000.0 in 2022, then plummeted by 31.43% to $72000.0 in 2023, then changed by 0.0% to $72000.0 in 2024, then skyrocketed by 83.33% to $132000.0 in 2025.
  • The last three reported values for Revenue were $132000.0 (Q4 2025), $70.6 million (Q3 2025), and $75000.0 (Q2 2025) per Business Quant data.